JavaScript отключён. Чтобы полноценно использовать наш сайт, включите JavaScript в своём браузере.

Ответить в теме

Сообщение: <blockquote data-quote="tumbesk" data-source="post: 737764" data-attributes="member: 11477"><p><a href=<a href="https://acialis.cfd">https://acialis.cfd</a>>buy cialis with paypal</a> whether and when drug applications may be filed in any additional jurisdictions for IBRANCE for potential HR HER2 metastatic breast cancer indications or in any jurisdictions for any other potential indications for IBRANCE; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of IBRANCE; and competitive developments</p></blockquote><p></p>